Literature DB >> 16260855

Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.

Luigi De Petris1, Ingmar Lax, Florin Sirzén, Signe Friesland.   

Abstract

The aim of this retrospective study was to evaluate the prognostic role of gross tumor volume (GTV) on survival of locally advanced NSCLC patients, regardless of TNM stage, and to analyze whether GTV and other radiotherapy (RT) parameters were important for the development of lung toxicity. Thirty-two patients with locally advanced NSCLC (stage IIIA bulky/IIIB) treated with chemoradiotherapy were retrospectively analyzed. Patients received induction chemotherapy followed by combination treatment (27 patients) or induction chemotherapy followed by RT alone (5 patients). Thoracic RT consisted in 60 Gy, with standard fractionation and was the same for all 32 patients. Dose volume histograms were collected from the 3D treatment plans and GTV, planning target volume, mean lung dose, volume of lung receiving more than 20 Gy or more than 30 Gy were analyzed. Survival was significantly longer in patients with a GTV < 100 cm(3) compared with patients having GTV > 100 cm(3) (p = 0.03). In a multivariate analysis only N-status and GTV were predictors of survival with a risk ratio of 0.51 and 0.62, respectively. Ten patients (31%) developed radiation pneumonitis grade 2 or higher. None of the RT parameters examined correlated significantly with the development of lung toxicity. In locally advanced NSCLC, GTV and N-status play a prognostic role even in patients at the same clinical stage and receiving a combination of chemo- and radiotherapy. This could imply a reassessment of the current staging system in patients with non-resectable NSCLC to better identify those patients who would benefit more from the combined treatment, despite its higher toxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16260855     DOI: 10.1385/MO:22:4:375

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  25 in total

Review 1.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

Authors:  David G Pfister; David H Johnson; Christopher G Azzoli; William Sause; Thomas J Smith; Sherman Baker; Jemi Olak; Diane Stover; John R Strawn; Andrew T Turrisi; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2003-12-22       Impact factor: 44.544

2.  Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy.

Authors:  Ellen D Yorke; Andrew Jackson; Kenneth E Rosenzweig; Scott A Merrick; Dorota Gabrys; Ennapadam S Venkatraman; Chandra M Burman; Steven A Leibel; C Clifton Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-10-01       Impact factor: 7.038

3.  Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer.

Authors:  Y Segawa; N Takigawa; M Kataoka; I Takata; N Fujimoto; H Ueoka
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-08-01       Impact factor: 7.038

4.  Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study.

Authors:  M Werner-Wasik; Y Xiao; E Pequignot; W J Curran; W Hauck
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-09-01       Impact factor: 7.038

5.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)

Authors:  M V Graham; J A Purdy; B Emami; W Harms; W Bosch; M A Lockett; C A Perez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-09-01       Impact factor: 7.038

6.  Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis.

Authors:  A Inoue; H Kunitoh; I Sekine; M Sumi; K Tokuuye; N Saijo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-01       Impact factor: 7.038

7.  Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer.

Authors:  Jochen Willner; Kurt Baier; Ekaterini Caragiani; Axel Tschammler; Michael Flentje
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

8.  Paclitaxel (Taxol) and carboplatin followed by concomitant paclitaxel, cisplatin and radiotherapy for inoperable stage III NSCLC.

Authors:  O P Isokangas; H Joensuu; M Halme; A Jekunen; K Mattson
Journal:  Lung Cancer       Date:  1998-05       Impact factor: 5.705

9.  Risk factors of pneumonitis following chemoradiotherapy for lung cancer.

Authors:  M Yamada; S Kudoh; K Hirata; T Nakajima; J Yoshikawa
Journal:  Eur J Cancer       Date:  1998-01       Impact factor: 9.162

10.  Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis.

Authors:  D Oetzel; P Schraube; F Hensley; G Sroka-Pérez; M Menke; M Flentje
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-09-30       Impact factor: 7.038

View more
  9 in total

Review 1.  Prediction of radiation pneumonitis in lung cancer patients: a systematic review.

Authors:  Xiao-Jing Zhang; Jian-Guo Sun; Jie Sun; Hua Ming; Xin-Xin Wang; Lei Wu; Zheng-Tang Chen
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-29       Impact factor: 4.553

Review 2.  Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.

Authors:  David A Palma; Suresh Senan; Kayoko Tsujino; Robert B Barriger; Ramesh Rengan; Marta Moreno; Jeffrey D Bradley; Tae Hyun Kim; Sara Ramella; Lawrence B Marks; Luigi De Petris; Larry Stitt; George Rodrigues
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-06-09       Impact factor: 7.038

3.  Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry.

Authors:  Jianjun Zhang; Kathryn A Gold; Heather Y Lin; Stephen G Swisher; Yan Xing; J Jack Lee; Edward S Kim; William N William
Journal:  J Thorac Oncol       Date:  2015-04       Impact factor: 15.609

4.  Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patients.

Authors:  Branislav Jeremić; Biljana Miličić; Slobodan Milisavljevic
Journal:  Clin Transl Oncol       Date:  2012-07-12       Impact factor: 3.405

5.  Integration of Risk Survival Measures Estimated From Pre- and Posttreatment Computed Tomography Scans Improves Stratification of Patients With Early-Stage Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy.

Authors:  Zhicheng Jiao; Hongming Li; Ying Xiao; Charu Aggarwal; Maya Galperin-Aizenberg; Daniel Pryma; Charles B Simone; Steven J Feigenberg; Gary D Kao; Yong Fan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-01-19       Impact factor: 7.038

6.  Mono-institutional phase 2 study of innovative Stereotactic Body RadioTherapy targeting PArtial Tumor HYpoxic (SBRT-PATHY) clonogenic cells in unresectable bulky non-small cell lung cancer: profound non-targeted effects by sparing peri-tumoral immune microenvironment.

Authors:  Slavisa Tubin; Mohammad K Khan; Gerardo Salerno; Waleed F Mourad; Weisi Yan; Branislav Jeremic
Journal:  Radiat Oncol       Date:  2019-11-26       Impact factor: 3.481

7.  Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: a subset analysis from a randomized clinical phase III trial.

Authors:  Hans H Strøm; Roy M Bremnes; Stein H Sundstrøm; Nina Helbekkmo; Ulf Aasebø
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

8.  A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer.

Authors:  Takaaki Hasegawa; Yohei Futamura; Akane Horiba; Tsutomu Yoshida; Toshitaka Suzuki; Tatsuo Kato; Daizo Kaito; Yasuhi Ohno; Takayoshi Iida; Shinya Hayashi; Toshiyuki Sawa
Journal:  J Radiat Res       Date:  2015-10-05       Impact factor: 2.724

Review 9.  Radiation-induced lung toxicity - cellular and molecular mechanisms of pathogenesis, management, and literature review.

Authors:  Lukas Käsmann; Alexander Dietrich; Claudia A Staab-Weijnitz; Farkhad Manapov; Jürgen Behr; Andreas Rimner; Branislav Jeremic; Suresh Senan; Dirk De Ruysscher; Kirsten Lauber; Claus Belka
Journal:  Radiat Oncol       Date:  2020-09-10       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.